Capitalizing Life Science Innovations

  Gain Therapeutics

Eric I. Richman, CEO and Director

Gain Therapeutics Inc. (NASDAQ: GANX)

“Working with Allele Capital reduced the risk of execution dramatically – their extensive industry knowledge in life sciences and contacts in the capital markets enabled a very predictable path for our company. Their entire team was engaged in our transaction and contributed in numerous ways to ensure the entire funding process was well executed. They provided value-added advice, proprietary investment, as well as institutional and accredited investors to support our company in a partnership-like approach. I would certainly recommend working with Allele Capital.”​